The round was led by U.S. Venture Partners and Longitude Capital.
Founded in 2002, Aptus is developing the Aptus Endovascular AAA Repair System, which provides an alternative to open surgical repair by separating the functions of aneurysm exclusion and endograft fixation. It includes both a proprietary Endograft and the EndoStapling System.
During 2010, the company obtained the CE Mark for the system
The new capital will be used to advance clinical and commercial development in Europe and continue the U.S. regulatory processes related to the Aptus EndoStapling System as both a stand-alone product and as part of the Aptus Endovascular AAA Repair System.
The company is also pursuing development for a thoracic aortic aneurysm (TAA) repair system and further innovation of its abdominal aortic aneurysm (AAA) repair system.